Shitanshu Uppal
GYOEDU Subscription FAQs
GYOEDU offers a tiered subscription system where each additional service
The Living Room
Originally featured in Publications Update # 77
Warning: This podcast episode
Keynote B21 - Pembrolizumab in High-Risk Endometrial Cancer (Video Explainer)
Video Explaining B-21 Trial
Keynote B-21: Pembrolizumab vs. Placebo in High-risk Endometrial Cancer
Adjuvant Pembrolizumab did not improve DFS in high-risk endometrial cancer population
HIPEC in ovarian cancer
Korean HIPEC trial - IDS patients only 2023
HIPEC combined with ICS significantly improved PFS and OS in advanced-stage ovarian cancer patients, without increasing the rate of severe postoperative complications. A notable reduction in peritoneal recurrence may contribute to the OS improvement.
Publications Update # 78
Medicine is Difficult article, discussion of interlace trial and PRIMA final survival data
Korean HIPEC trial
The addition of HIPEC after interval cytoreductive surgery following neoadjuvant chemotherapy provided significant improvements in PFS and OS.
Interlace Trial
Induction chemotherapy followed by chemoradiotherapy significantly improves both progression-free survival and overall survival in patients with locally advanced cervical cancer compared to chemoradiotherapy alone.